Global Prostate Cancer Diagnostics Market - Industry Trends and Forecast to 2028

Segmentation

Short Description
Global Prostate Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables and Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer and Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic), Sample Type (Blood, Tissue, Urine and Others), End Users (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, U.K., Italy, Spain, Russia, Switzerland, Netherlands, Belgium, Turkey, Ireland and Rest of Europe, Japan, China, Australia, South Korea, India, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, U.S., Canada, Mexico, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, UAE, Israel and Rest of Middle East and Africa)-Industry Trends & Forecast to 2028        

Market Definition:
The prostate cancer begins when the cells in the prostate gland started to grow at an abnormal pace and the condition is known to be prostate cancer. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. The prostate cancer diagnostics is a technique of detection of cancer mainly in the early stage to conduct the future treatment approach which can increase the survival rate. It includes in-vitro diagnosis, medical imagining among others used as the diagnostics approach for the prostate cancer detection and some advanced diagnostics method approved in the recent past. The improper or inaccurate diagnosis of prostate cancer leads to wrong treatment which cause extra burden on the patients pocket and cause decrease in reliability for the diagnostics products.
Market Segmentation:
Prostate cancer diagnostics market is categorized into product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.

 On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories.
 On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests
 On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics.
 On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others.
 On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic).
 On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others.
 On the basis of end user, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others
 On the basis of distribution type, the prostate cancer diagnostics market is segmented into direct tender and retail sales.



 Market Players

The key market players for the global prostate cancer diagnostics market are listed below:

 FF. Hoffmann-La Roche Ltd
 ACON Laboratories, Inc.
 HUMASIS
 Teco Diagnostics
 Hologic Inc.
 Accuquik Test Kits
 MDxHealthcare
 Abbott
 Siemens Healthcare GmbH
 OPKO Health Inc.
 Myraid Genetics, Inc.
 DiaSorin S.p.A
 Beckman Coulter, Inc. (a subsidiary of Danaher)
 Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation)
 bioMrieux SA
 Metamark Genetics, Inc.
 Prostatype Genomics
 Fujirebio
 Proteomedix
 Eurolyser Diagnostica GmbH

Methodology